Loading organizations...
LabGenomics is a South Korea-based healthcare company specializing in molecular diagnostics, genetic tests, and NGS-based cancer diagnostics (BRCA1/BRCA2, comprehensive panels, OTD-Solid tests). The publicly traded KOSDAQ entity (084650), founded in 2002, develops genetic analysis devices, DNA chips, PCR kits, and POCT solutions for preventive and personalized medicine. Led by CEO Kim Jung-joo, the company expanded into the US market by acquiring QDx Pathology via LabGenomics USA, headed by Junghee Cho, Ph.D. LabGenomics also partners with Amorepacific for consumer gene testing services, such as MySkin DNA. With 142 employees, LabGenomics reported 87.97 billion KRW in TTM revenue and a market capitalization of 177.80 billion KRW. Its business model centers on publicly traded company generating revenue from diagnostic services, genetic testing products, and partnerships like gene testing supply deals.
LabGenomics has 1 tracked investment across 1 company. The latest tracked deal is $20.0M Series B in Rebus Biosystems in November 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 19, 2020 | Rebus Biosystems | $20.0M Series B | TOM Willis | CTK Investments, Lifecore Partners, NCORE Ventures, RAY, Seegene Medical Foundation, Timefolio Asset Management, Xoloninvest |
